Andrew Perry is Chief Commercial Officer at G1 Therapeutics, Inc. (GTHX). They have made 4 open-market trades across 1 company since 2023, most recently 2024-09-18.
CIK 0001877793
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GTHX | 14,232 | $102K |
Shares reported on the most recent Form 4, priced at the 2024-09-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GTHX | SELL | 2024-07-05 | 2024-07-08 | $2.51 | $3K | +42.2% | +175.8% | N/A |
| GTHX | SELL | 2024-05-13 | 2024-05-15 | $4.79 | $39K | -26.2% | -39.7% | +53.6% |
| GTHX | SELL | 2024-01-03 | 2024-01-08 | $3.12 | $8K | +1.8% | +43.8% | +42.0% |
| GTHX | SELL · 10b5-1 | 2023-07-05 | 2023-07-07 | $2.45 | $870 | +10.8% | -15.8% | -47.3% |
| GTHX | SELL | 2023-01-04 | 2023-01-05 | $5.58 | $5K | +24.8% | +45.1% | -51.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.